ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2004
Pharmacokinetics/pharmacodynamics of echinocandins.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Updated antimicrobial dosing recommendations for obese patients.Antimicrobial agents and chemotherapy · 2024Pooled it
- Micafungin Sequestration and Late Release During Continuous Renal Replacement Therapy with Polyacrylonitrile- and Polysulfone-Derived Filters.Infectious diseases and therapy · 2026Article
- Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives.Infectious disease reports · 2025Review
- Management of Intra-Abdominal Candidiasis in Intensive Care Setting: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Development of an in vitro pharmacokinetic/pharmacodynamic model in the presence of serum for studying micafungin activity against Candida albicans: a need for revision of CLSI susceptibility breakpoints.The Journal of antimicrobial chemotherapy · 2023Article
- Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?Antibiotics (Basel, Switzerland) · 2022Review
- Pharmacokinetics/Pharmacodynamics of Caspofungin in Plasma and Peritoneal Fluid of Liver Transplant Recipients.Antimicrobial agents and chemotherapy · 2022Article
- Precision Therapy for Invasive Fungal Diseases.Journal of fungi (Basel, Switzerland) · 2021Article
- Assessment of Micafungin Dosage Regimens in Patients with Cancer Using Pharmacokinetic/Pharmacodynamic Modeling and Monte Carlo Simulation.Antibiotics (Basel, Switzerland) · 2021Article
- Synthesis, Optimization, Antifungal Activity, Selectivity, and CYP51 Binding of New 2-Aryl-3-azolyl-1-indolyl-propan-2-ols.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Methodologies forMicrobial cell (Graz, Austria) · 2018Review
- Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.Antimicrobial agents and chemotherapy · 2015Article
- Limited-sampling strategies for anidulafungin in critically ill patients.Antimicrobial agents and chemotherapy · 2015Article
- Treatment with echinocandins during continuous renal replacement therapy.Critical care (London, England) · 2014Review
- Tissue penetration of antifungal agents.Clinical microbiology reviews · 2014Review
- Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous model.Antimicrobial agents and chemotherapy · 2013Article
- In vitro antifungal activity of micafungin and caspofungin against dermatophytes isolated from China.Mycopathologia · 2013Article
- Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents.BioMed research international · 2013Review
- Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections.Antimicrobial agents and chemotherapy · 2013Article
- Pharmacokinetics of caspofungin in two patients with burn injuries.Antimicrobial agents and chemotherapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel class of echinocandins represents a milestone in antifungal drug research that has further expanded our therapeutic options. The favorable pharmacokinetic profile of the echinocandins has been elucidated in animal and human studies. The echinocandins are targeted for once-daily dosing and are not metabolized through the cytochrome P450 enzyme system, and they are generally well tolerated due to lack of mechanism-based toxicity. Little is known, however, about the disposition of these compounds in tissues and body fluids and the relationships between dosage, concentrations in the body, and antifungal efficacy in vivo. Many unanswered questions remain, including the importance of the high protein binding and the concentrations of free antifungal agents at target sites. Although recent attempts have been made to ensure the reproducibility of in vitro tests, the clinical usefulness of these tests is still unreliable and their relevance remains controversial. In vitro activity must be correlated with achievable concentrations at the site of infection. As little is known about the relationship between the pharmacokinetics and the pharmacodynamics of the echinocandins, increased incorporation of these principles in experimental and clinical studies is an important objective that will benefit the treatment and prophylaxis of life-threatening invasive fungal infections in immunocompromised patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.